Horizon Technology Finance offers an attractive investment mix and has the potential for high total returns. The BDC suffered a deterioration in credit quality but still maintains robust dividend ...
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today ...
Bolt Biotherapeutics reported clinical updates and financial results, highlighting BDC-4182's upcoming trial and completed enrollment for BDC-3042. Bolt Biotherapeutics has announced significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback